| http://www.w3.org/ns/prov#value | - Adverse events including bleeding did not differ between the groups (103).A 2012 randomized, controlled trial compared aspirin, 100 mg/d, to placebo in 822 patients who had completed therapy for a first episode of unprovoked VTE. After 37 months follow-up, there was a nonsignificant trend toward reduced recurrent VTE in the aspirin group (6.5% in the placebo group vs. 4.8% in the aspirin group, P=
|
